WO1997023783A9 - Procede de mesure et de traitement fondes sur la presence de produits terminaux de glycosylation poussee dans le tabac et dans ses sous-produits de combustion - Google Patents
Procede de mesure et de traitement fondes sur la presence de produits terminaux de glycosylation poussee dans le tabac et dans ses sous-produits de combustionInfo
- Publication number
- WO1997023783A9 WO1997023783A9 PCT/US1996/020526 US9620526W WO9723783A9 WO 1997023783 A9 WO1997023783 A9 WO 1997023783A9 US 9620526 W US9620526 W US 9620526W WO 9723783 A9 WO9723783 A9 WO 9723783A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tobacco
- ages
- age
- smoke
- glycotoxins
- Prior art date
Links
- 241000208125 Nicotiana Species 0.000 title claims abstract description 235
- 235000002637 Nicotiana tabacum Nutrition 0.000 title claims abstract description 235
- 108010005094 Advanced Glycation End Products Proteins 0.000 title claims abstract description 229
- 238000005259 measurement Methods 0.000 title claims abstract description 20
- 238000002485 combustion reaction Methods 0.000 title claims abstract description 18
- 239000006227 byproduct Substances 0.000 title claims abstract description 16
- 239000000779 smoke Substances 0.000 claims abstract description 178
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 67
- 230000000391 smoking Effects 0.000 claims abstract description 64
- 239000000047 product Substances 0.000 claims abstract description 47
- 239000000463 material Substances 0.000 claims abstract description 37
- 238000009825 accumulation Methods 0.000 claims abstract description 22
- 230000003899 glycosylation Effects 0.000 claims abstract description 19
- 238000006206 glycosylation reaction Methods 0.000 claims abstract description 19
- 238000003860 storage Methods 0.000 claims abstract description 9
- 230000000875 corresponding Effects 0.000 claims abstract description 8
- 235000019504 cigarettes Nutrition 0.000 claims description 123
- 102000004169 proteins and genes Human genes 0.000 claims description 68
- 108090000623 proteins and genes Proteins 0.000 claims description 68
- 230000015572 biosynthetic process Effects 0.000 claims description 64
- 238000005755 formation reaction Methods 0.000 claims description 62
- 230000036252 glycation Effects 0.000 claims description 56
- 210000002966 Serum Anatomy 0.000 claims description 55
- 108090001123 antibodies Proteins 0.000 claims description 48
- 102000004965 antibodies Human genes 0.000 claims description 48
- 230000002401 inhibitory effect Effects 0.000 claims description 48
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 claims description 46
- 238000006243 chemical reaction Methods 0.000 claims description 43
- 239000000523 sample Substances 0.000 claims description 38
- 230000000694 effects Effects 0.000 claims description 36
- 239000000284 extract Substances 0.000 claims description 34
- 235000000346 sugar Nutrition 0.000 claims description 30
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 27
- 239000008103 glucose Substances 0.000 claims description 27
- 150000008163 sugars Chemical class 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 19
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 17
- 125000003277 amino group Chemical group 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 14
- -1 analogs Substances 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 9
- 238000004132 cross linking Methods 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 230000002939 deleterious Effects 0.000 claims description 8
- 230000003053 immunization Effects 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 239000000758 substrate Substances 0.000 claims description 7
- 102000014914 Carrier Proteins Human genes 0.000 claims description 6
- 108010078791 Carrier Proteins Proteins 0.000 claims description 6
- 239000012472 biological sample Substances 0.000 claims description 6
- 239000000969 carrier Substances 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 239000000543 intermediate Substances 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 210000003608 Feces Anatomy 0.000 claims description 3
- 210000002700 Urine Anatomy 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 239000000039 congener Substances 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 3
- 230000003278 mimic Effects 0.000 claims description 3
- 210000003296 Saliva Anatomy 0.000 claims description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 2
- 125000003172 aldehyde group Chemical group 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 125000004997 halocarbonyl group Chemical group 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical group CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims description 2
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical group CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 1
- 125000001145 hydrido group Chemical group *[H] 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000001965 increased Effects 0.000 abstract description 23
- 235000019505 tobacco product Nutrition 0.000 abstract description 22
- 239000012298 atmosphere Substances 0.000 abstract description 15
- 238000011156 evaluation Methods 0.000 abstract description 6
- 235000018102 proteins Nutrition 0.000 description 65
- 238000004166 bioassay Methods 0.000 description 45
- 239000002953 phosphate buffered saline Substances 0.000 description 29
- 102000008186 Collagen Human genes 0.000 description 25
- 108010035532 Collagen Proteins 0.000 description 25
- 229920001436 collagen Polymers 0.000 description 25
- 229960005188 collagen Drugs 0.000 description 25
- 238000000034 method Methods 0.000 description 25
- 238000002965 ELISA Methods 0.000 description 20
- 230000035508 accumulation Effects 0.000 description 19
- 239000003112 inhibitor Substances 0.000 description 19
- 210000001519 tissues Anatomy 0.000 description 18
- 210000004369 Blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- 102000007330 LDL Lipoproteins Human genes 0.000 description 16
- 108010007622 LDL Lipoproteins Proteins 0.000 description 16
- 238000000338 in vitro Methods 0.000 description 16
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 15
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 206010012601 Diabetes mellitus Diseases 0.000 description 13
- 230000002860 competitive Effects 0.000 description 13
- 238000010790 dilution Methods 0.000 description 13
- 230000003505 mutagenic Effects 0.000 description 11
- 230000032683 aging Effects 0.000 description 10
- 239000006286 aqueous extract Substances 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 101700065507 APOB Proteins 0.000 description 9
- 108090000745 Immune Sera Proteins 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 210000004027 cells Anatomy 0.000 description 9
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 108010045030 monoclonal antibodies Proteins 0.000 description 9
- 102000005614 monoclonal antibodies Human genes 0.000 description 9
- 229960003890 pimagedine Drugs 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 239000002609 media Substances 0.000 description 8
- 230000001225 therapeutic Effects 0.000 description 8
- 241000283707 Capra Species 0.000 description 7
- 229940045189 Glucose-6-Phosphate Drugs 0.000 description 7
- NBSCHQHZLSJFNQ-GASJEMHNSA-N Glucose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 7
- 210000004408 Hybridomas Anatomy 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 238000006011 modification reaction Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 206010003210 Arteriosclerosis Diseases 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- 210000002435 Tendons Anatomy 0.000 description 6
- 150000001299 aldehydes Chemical group 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 201000001320 atherosclerosis Diseases 0.000 description 6
- 230000001580 bacterial Effects 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 230000001717 pathogenic Effects 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 241000894007 species Species 0.000 description 6
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical class C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 6
- 239000003656 tris buffered saline Substances 0.000 description 6
- 210000004072 Lung Anatomy 0.000 description 5
- 210000003491 Skin Anatomy 0.000 description 5
- 210000000515 Tooth Anatomy 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007172 antigens Proteins 0.000 description 5
- 102000038129 antigens Human genes 0.000 description 5
- 230000000981 bystander Effects 0.000 description 5
- 230000001413 cellular Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 201000008739 coronary artery disease Diseases 0.000 description 5
- 230000001419 dependent Effects 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 231100000350 mutagenesis Toxicity 0.000 description 5
- 231100000219 mutagenic Toxicity 0.000 description 5
- 231100000243 mutagenic effect Toxicity 0.000 description 5
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 125000002306 tributylsilyl group Chemical group C(CCC)[Si](CCCC)(CCCC)* 0.000 description 5
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl dihydrogen phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000000240 adjuvant Effects 0.000 description 4
- 239000001058 brown pigment Substances 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000000984 immunochemical Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000003287 optical Effects 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 201000011528 vascular disease Diseases 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 210000001124 Body Fluids Anatomy 0.000 description 3
- 210000000170 Cell Membrane Anatomy 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 210000000497 Foam Cells Anatomy 0.000 description 3
- 210000002540 Macrophages Anatomy 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 210000000952 Spleen Anatomy 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 230000036462 Unbound Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000003570 air Substances 0.000 description 3
- 239000012080 ambient air Substances 0.000 description 3
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 3
- 230000003143 atherosclerotic Effects 0.000 description 3
- 230000000903 blocking Effects 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000003247 decreasing Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 210000002257 embryonic structures Anatomy 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229960000060 monoclonal antibodies Drugs 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001575 pathological Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000002831 pharmacologic agent Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000003389 potentiating Effects 0.000 description 3
- 230000002829 reduced Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 102100001249 ALB Human genes 0.000 description 2
- 101710027066 ALB Proteins 0.000 description 2
- 102000018616 Apolipoproteins B Human genes 0.000 description 2
- 108010027006 Apolipoproteins B Proteins 0.000 description 2
- 210000002808 Connective Tissue Anatomy 0.000 description 2
- 208000004981 Coronary Disease Diseases 0.000 description 2
- 210000000805 Cytoplasm Anatomy 0.000 description 2
- 206010058108 Dyslipidaemia Diseases 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 206010072082 Environmental exposure Diseases 0.000 description 2
- 229940088598 Enzyme Drugs 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 230000036499 Half live Effects 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 102000000853 LDL receptors Human genes 0.000 description 2
- 108010001831 LDL receptors Proteins 0.000 description 2
- 206010061227 Lipid metabolism disease Diseases 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 208000009856 Lung Disease Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 description 2
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 206010039447 Salmonellosis Diseases 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229940050528 albumin Drugs 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000003197 catalytic Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000001055 chewing Effects 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 235000019506 cigar Nutrition 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 230000003467 diminishing Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000002657 fibrous material Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- 238000009114 investigational therapy Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000003902 lesions Effects 0.000 description 2
- 210000004962 mammalian cells Anatomy 0.000 description 2
- 230000018984 mastication Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000310 mutation rate increase Toxicity 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- 230000003472 neutralizing Effects 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000004738 parenchymal cell Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002685 pulmonary Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 239000001052 yellow pigment Substances 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N 1,2,3-propanetrioltrinitrate Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- VTYFITADLSVOAS-NSHDSACASA-N 1-(L-norleucin-6-yl)pyrraline Chemical compound OC(=O)[C@@H](N)CCCCN1C(CO)=CC=C1C=O VTYFITADLSVOAS-NSHDSACASA-N 0.000 description 1
- UBDZFAGVPPMTIT-UHFFFAOYSA-N 2-aminoguanidine;hydron;chloride Chemical compound [Cl-].NC(N)=N[NH3+] UBDZFAGVPPMTIT-UHFFFAOYSA-N 0.000 description 1
- 229960004373 Acetylcholine Drugs 0.000 description 1
- 206010003119 Arrhythmia Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006451 Bronchitis Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010007521 Cardiac arrhythmias Diseases 0.000 description 1
- 208000008787 Cardiovascular Disease Diseases 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000007451 Chronic Bronchitis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 210000004351 Coronary Vessels Anatomy 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000014824 Crystallins Human genes 0.000 description 1
- 108010064003 Crystallins Proteins 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 206010061835 Diabetic nephropathy Diseases 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 210000002889 Endothelial Cells Anatomy 0.000 description 1
- 208000003401 Eosinophilic Granuloma Diseases 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 208000008754 Esophageal Disease Diseases 0.000 description 1
- 210000002744 Extracellular Matrix Anatomy 0.000 description 1
- 210000003754 Fetus Anatomy 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N Glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
- 210000003128 Head Anatomy 0.000 description 1
- 102000007513 Hemoglobin A Human genes 0.000 description 1
- 108010085682 Hemoglobin A Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010062060 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010000345 Immobilized Antibodies Proteins 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 229940078795 Lactoferrin Drugs 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 210000000282 Nails Anatomy 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 229940014995 Nitroglycerin Drugs 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010030201 Oesophageal ulcer Diseases 0.000 description 1
- 208000004179 Oral Leukoplakia Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010034636 Peripheral vascular disease Diseases 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- 206010062080 Pigmentation disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 208000003782 Raynaud Disease Diseases 0.000 description 1
- 206010037912 Raynaud's phenomenon Diseases 0.000 description 1
- 208000006265 Renal Cell Carcinoma Diseases 0.000 description 1
- 206010038435 Renal failure Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 229960001052 Streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- OBTWBSRJZRCYQV-UHFFFAOYSA-N Sulfuryl fluoride Chemical compound FS(F)(=O)=O OBTWBSRJZRCYQV-UHFFFAOYSA-N 0.000 description 1
- 102100008471 THBD Human genes 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 108010079274 Thrombomodulin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 229960002175 Thyroglobulin Drugs 0.000 description 1
- 210000004291 Uterus Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000004887 air purification Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 230000002429 anti-coagulation Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- 238000003556 assay method Methods 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 102000024070 binding proteins Human genes 0.000 description 1
- 108091007650 binding proteins Proteins 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 201000001084 cerebrovascular disease Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 125000004989 dicarbonyl group Chemical group 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000002414 glycolytic Effects 0.000 description 1
- 238000004442 gravimetric analysis Methods 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 201000010238 heart disease Diseases 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 230000003345 hyperglycaemic Effects 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 231100000824 inhalation exposure Toxicity 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- 125000001553 ketosyl group Chemical group 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 108091005526 macrophage scavenger receptors Proteins 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 238000007392 microtiter assay Methods 0.000 description 1
- 230000001617 migratory Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
- 230000036438 mutation frequency Effects 0.000 description 1
- 230000001613 neoplastic Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 239000006833 oxoid nutrient broth Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- AYEKKSTZQYEZPU-RYUDHWBXSA-N pentosidine Chemical compound OC(=O)[C@@H](N)CCCCN1C=CC=C2N=C(NCCC[C@H](N)C(O)=O)N=C12 AYEKKSTZQYEZPU-RYUDHWBXSA-N 0.000 description 1
- 230000000737 periodic Effects 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 230000036231 pharmacokinetics Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000002947 procoagulant Effects 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 230000013595 protein glycosylation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 230000002441 reversible Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 230000003381 solubilizing Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 230000000087 stabilizing Effects 0.000 description 1
- 230000000153 supplemental Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229940055329 tobacco leaf extract Drugs 0.000 description 1
- 230000036344 tooth staining Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000004869 vascular alteration Effects 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Definitions
- the present invention relates generally to the correlation between the use of tobacco products such as cigarettes, and the presence of advanced glycosylation endproducts (AGEs), and to the diagnostic, therapeutic and industrial applications to which this observation and relationship may be beneficially directed. More particularly, the invention directs itself to the observation that the consumption of tobacco products increases the amount of AGEs in vivo, with concomitant increases in risk and incidence of maladies associated with both smoking and AGE accumulation, and to the detection of AGEs in tobacco, tobacco smoke and extracts thereof, as well as in tobacco users, both to detect undesirable excesses in AGE levels and to evaluate tobacco and smoking materials on a commercial scale.
- the invention also extends to the use of inhibitors of the formation of AGEs in a variety of contexts to treat or prevent undesirable excesses in AGE levels, as well as to modify tobacco and smoking materials on a commercial scale.
- hemoglobin A lc modified hemoglobin
- the Maillard browning process generates a widely diverse array of advanced glycosylation products, each of which occurs in very low yield. This diversity has made identification and structural determination of specific AGEs a difficult proposition.
- U.S. Patent No. 4,665,192 the fluorescent chromophore 2-(2- furoyl)-4(5)-2(furanyl)-lH-imidazole was isolated and identified from certain browned polypeptides such as bovine serum albumin and poly-L-lysine. This success encouraged the subsequent identification of additional advanced glycosylation endproducts and assisted additional investigations seeking to clarify the chemistry of the protein aging process and to identify the specific reactants, intermediates and products involved in order to develop methods and agents for inhibiting glycation.
- Oxidation and glycation of the protein and lipid components of low- density lipoprotein (LDL) results in the loss of the recognition of the apo B component by cellular LDL receptors, prolonging the circulating half-life of this LDL and resulting in the preferential uptake of oxidized-LDL (ox-LDL) or otherwise modified LDL via macrophage "scavenger" receptors, AGE receptors, and other specialized cellular mechanisms.
- ox-LDL oxidized-LDL
- AGE receptors AGE receptors
- AGE-lipids may also be stable, unstable or reactive.
- inhibitors of advanced glycation reactions are also known, many of which are thought to be particularly effective at stages of the Maillard reaction other than those which are most susceptible to inhibition by aminoguanidine and its analogs.
- certain compounds, or compositions thereof, having an active aldehyde substituent, such as acetaldehyde are effective inhibitors of the advanced glycation pathway. This activity is thought to arise by the reaction of such active aldehyde agents with the glycosyl-amino moieties of glycation products formed in the initial stages of the Maillard reaction, i.e., these agents react with the Amadori and Heyns rearrangement products, which are early glycation products.
- agents that may serve in a similar capacity, are those that include a conserved binding motif which comprises a common 17-18 amino acid cysteine- bounded hydrophilic peptide loop domain, initially discovered and identified in the antibacterial proteins lysozyme and lactoferrin.
- R,Z,Xaa_Z 2 R 2 SEQ ID NOS: 1-6
- Z, and Z 2 are residues capable of forming a cross-link
- R, and R 2 are independently a polypeptide, a C, to C )2 alkyl, aryl, heteroalkyl, or heteroaryl group, or hydrogen
- Xaa is any L- or D- amino acid
- n 13-18.
- Yet other agents such as certain thiazolium compounds, are particularly effective at preventing advanced glycation, and even reversing the formation of advanced glycation endproducts and associated cross-linking moieties, through reactions with late glycation products.
- the compounds, and their compositions, utilized in this invention are thought to react with early glycosylation products, thereby preventing the same from later forming the advanced glycosylation end products which lead to cross-links, and thereby, to molecular or protein aging and other adverse molecular consequences. All of such various glycation pathway inhibitors and other compounds reactive with early and late glycation products, either alone or in combination, find use in ameliorating the pathogenic potential of AGEs that accumulate in the body.
- AGEs may accumulate through de novo formation in vivo, through reattachment of AGEs liberated in vivo by cellular activities, or as revealed herein by Applicants, by exposure to exogenous AGEs, for instance by smoking. Accordingly, the significance of the reactive pathways of AGEs and their observed presence in tobacco and tobacco smoke lends further importance and encouragement to the need for the development of effective techniques for monitoring the smoking habits of individuals, as well as the development of effective agents and devices to reduce the transfer of AGEs by tobacco use. Such monitoring techniques would be useful for gathering the history of such smokers, and also for monitoring their medical condition and particularly, their predisposition to the conditions that are associated with elevated levels of AGEs.
- Measurement of AGEs in tobacco would facilitate the evaluation of tobacco crops, as well as providing an index of the amount of AGEs that would be transferred to a smoker during the consumption of smoking materials prepared from the crops in question; in this regard, AGEs may also be evaluated in tobacco smoke.
- Effective therapeutic strategies, methods and agents in this regard may address the inhibition of AGEs in tobacco, in smoking materials, and would include the development of filter devices and like materials for use in conjunction with tobacco smoking, or in the protection or treatment of individuals of the smoking or smoke-exposed populations. It is toward the fulfillment of all of the above recited objectives that the present invention is directed.
- the present invention derives from the discovery that tobacco and its combustion byproducts such as smoke, contain advanced glycosylation endproducts (AGEs) which are, as a group, reactive with amine-containing biomolecules, especially proteins, and that consequently, individuals who smoke or otherwise use tobacco generally exhibit increases in AGE levels throughout the blood and tissues.
- AGEs advanced glycosylation endproducts
- the elevation in such levels has been linked to the increased incidence of the pathologies, such as increased risk for coronary disease, atherosclerosis and other maladies, associated with enhanced accumulation of AGEs.
- the invention recognizes the presence of AGEs in tobacco, tobacco products for use as by smoking, and the combustion byproducts of tobacco and in biological samples taken from smokers.
- the invention extends to the measurement of AGEs in tobacco smoking materials, in the combustion byproducts of tobacco, and in biological samples taken from smokers, to identify AGE levels and to thereby facilitate an estimate of the likelihood or history of exposure of an individual to such AGEs during smoking, or to provide information on the condition of the tobacco or tobacco products including, for example, to evaluate the age, flavor and/or storage status (freshness) of a tobacco crop.
- the measurement and evaluation of smokers would serve both to apprise the healthcare professional and the patient of any pathological conditions that may either have a high likelihood of onset, or that, if present, bear close periodic monitoring and/or indicate the need for therapeutic intervention, and to assess the extent and consequent risk that the smoker assumes from the smoking habit.
- the latter consideration would attend the evaluation of the patient as participant in a program for the purpose of stopping smoking, as well as to assess the extent of the test subject's smoking history, for insurance or like investigative purposes to confirm the cessation of tobacco use (or lack thereof).
- the measurement of AGEs may be made by treating a sample of tobacco to form an extract in which AGEs are suspected to be present, followed by the analysis of the extract for such purpose.
- the sample may be treated by combustion to form smoke, and the smoke is then examined for the presence and amount of AGEs.
- the extract may proceed from a chemical treatment of the tobacco alone.
- One may also examine the body fluids and tissues of the smoker to determine the level and extent of AGEs present as a result of smoking. The results would be compared to a standard developed from non-smoking individuals otherwise sharing the same medical profile as the patient under test.
- the invention includes the preparation of agents to specifically recognize tobacco- relate AGEs, such as antibodies that are specifically directed against the AGEs found in tobacco and tobacco smoke, to facilitate the detection of tobacco-related AGEs and the evaluation of the medical status of tobacco smokers.
- agents to specifically recognize tobacco- relate AGEs such as antibodies that are specifically directed against the AGEs found in tobacco and tobacco smoke, to facilitate the detection of tobacco-related AGEs and the evaluation of the medical status of tobacco smokers.
- agents to specifically recognize tobacco- relate AGEs such as antibodies that are specifically directed against the AGEs found in tobacco and tobacco smoke, to facilitate the detection of tobacco-related AGEs and the evaluation of the medical status of tobacco smokers.
- agents to specifically recognize tobacco- relate AGEs such as antibodies that are specifically directed against the AGEs found in tobacco and tobacco smoke
- dosimeters may be prepared with a substrate or carrier retaining and bearing a glycation target molecule, such as an amine-bearing moiety, fixedly associated therewith, and capable of reacting with AGEs present in a sample, be it a sample of ambient air or a biological sample taken from a patient.
- a glycation target molecule such as an amine-bearing moiety
- the dosimeter may be used in conjunction with the diagnostic protocols and test kits set forth herein.
- the invention further extends to methods for detecting and measuring the levels of advanced glycosylation endproducts in individuals who smoke tobacco, by gathering a biological sample from such individuals and thereafter examining the sample for the presence and amount of advanced glycosylation endproducts.
- the sample gathered may extend to cells, tissue, serum, saliva, urine or feces, and the techniques for detection and measurement have been developed and utilized with respect to AGEs in the past.
- the invention extends to the preparation of antagonists such as antibodies, binding motifs and chemical inhibitors of advanced glycation that are specifically directed against the AGEs found in tobacco and tobacco smoke.
- the present invention also extends to a method and associated agents for use in the treatment of conditions in individuals who are tobacco users or smokers, which comprise such methods and agents as are useful for the inhibition of protein aging and particularly, such agents as are capable of reacting with glycosylation products to counteract their formation and/or the deleterious activity of such AGEs.
- agents for inhibiting protein aging due to the formation of advanced glycosylation endproducts may be selected from the group consisting of aminoguanidine; agonists, analogs, congeners, cognates and mimics thereof; and mixtures thereof.
- Such agents may also include and may be selected from materials capable of reacting with the glycosyl-amino moiety of the early glycosylation product (also known as the Amadori and Heyns products) formed by the reaction of glucose, or other reactive sugars, with a biomolecule presenting a glycation-susceptible moiety, such as an amino group on a protein, thus stabilizing this early glycosylation product, and preventing its further reaction to form advanced glycosylation end products.
- the early glycosylation product also known as the Amadori and Heyns products
- a biomolecule presenting a glycation-susceptible moiety, such as an amino group on a protein
- these agents may comprise compounds that participate in the formation of products having either formula I or II
- R is the residue of an amino-containing peptide or protein, prepared by reacting the glycosyl-amino moiety of the early glycosylation product (also known as the Amadori or Heyns product) formed by the reaction of glucose, or other reactive sugars, with a protein, with an agent containing a reactive aldehyde group.
- the early glycosylation product also known as the Amadori or Heyns product
- an agent containing a reactive aldehyde group Typical agents of this class are described in Provisional Application Serial No. 60/006,752, for "Improved Method and Agent for Inhibiting Protein Aging," filed November 15, 1995. which is inco ⁇ orated herein by reference.
- agents such as certain thiazolium compounds
- thiazolium compounds are particularly effective at preventing advanced glycation, and even reversing the formation of advanced glycation endproducts and associated cross-linking moieties, through reactions with late glycation products.
- Exemplary compounds and compositions that are effective against pre-existing or late glycation adducts are thought to operate by reacting with, and causing the cleavage of, ⁇ -dicarbonyl segments within existing AGEs, particularly as such ⁇ -dicarbonyl segments occur within AGE structures that form inter- or intra-molecular cross-links.
- thiazolium-based compounds preferably operate in this regard in a catalytic fashion which regenerates the original, active thiazolium derivative that may then catalyze the cleavage of additional existing AGE moieties.
- Typical agents of this class may comprise thiazolium compounds having the following structural formula:
- R 1 and R 2 are independently selected from the group consisting of hydrogen, hydroxy(lower)alkyl, acetoxy(lower)alkyl, lower alkyl, lower alkenyl, or R' and R 2 together with their ring carbons may be an aromatic fused ring, optionally substituted by one or more amino, halo or alkylenedioxy groups;
- Z is hydrogen or an amino group;
- Y is amino, a group of the formula O w
- R is a lower alkyl, alkoxy, hydroxy, amino or an aryl group, said aryl group optionally substituted by one or more lower alkyl, lower alkoxy, halo. dialkylamino, hydroxy, nitro or alkylenedioxy groups; a group of the formula -CH 2 R' wherein R' is hydrogen, or a lower alkyl, lower alkynyl, or aryl group; or a group of the formula
- R" is hydrogen and R" ' is a lower alkyl group, optionally substituted by an aryl group, or an aryl group, said aryl group optionally substituted by one or more lower alkyl, halo, or alkoxylcarbonyl groups; or R" and R'" are both lower alkyl groups;
- X is a halide, tosylate, methanesulfonate or mesitylenesulfonate ion; and mixtures thereof.
- the compounds, and their compositions, utilized in this invention are thought to react with early glycosylation products, thereby preventing the same from later forming the advanced glycosylation end products which lead to cross-links, and thereby, to molecular or protein aging and other adverse molecular consequences. Additionally, said compounds and compositions are thought to react with already formed advanced glycosylation end products to reduce the amount of such products. These agents are described in greater detail in Application Serial No. 08/375,155, which is inco ⁇ orated herein by reference.
- the present invention further extends to methods for the reduction of the accumulation of advanced glycosylation endproducts particularly in individuals who are tobacco smokers or otherwise consume tobacco products, by treating such individuals with agents that are known to inhibit the formation of advanced glycosylation endproducts, such as those agents set forth above herein.
- Said agents find particular utility in the several diseases and pathological conditions the incidence or severity of which has been associated with tobacco consumption, especially by cigarette smoking, such as cardiovascular, cerebrovascular and peripheral vascular diseases including, for instance, heart and coronary artery disease, arrhythmia, atherosclerosis, stroke, hypertension, pulmonary infection, thromboangiitis obliterans, peripheral occlusive vascular disease, Raynaud's disease, claudication and renal failure; pulmonary and lung diseases such as chronic obstructive pulmonary disease, chronic bronchitis, emphysema, asthma, and eosinophilic granuloma of the lung; various cancers including, without limitation, lung cancer, cancer of the mouth, head and neck, mesothelioma, esophageal, bladder, cervical, endometrial, pancreatic and renal cell cancer; peptic, gastric and esophageal ulcer; hyperlipidemia and dyslipidemia: osteoporosis; scler
- the present method extends to the treatment of the tobacco materials themselves to reduce the generation as well as the passage of such AGEs to the consumer or bystander.
- the method would comprise the treatment of the tobacco materials themselves by chemical means or otherwise, to reduce the formation or presence of advanced glycosylation endproducts.
- certain tobaccos are cured with sugar, such method could extend to the treatment of the cured tobacco so that a reduction in the content of AGEs or their precedent glycotoxins as defined herein, is accomplished.
- a further embodiment of the treatment of the tobacco materials would comprise the preparation of an appropriate filter medium for use in conjunction with the tobacco endproduct or cigarette, which filter medium would be treated with agents such as those set forth herein known to be inhibitors of advanced glycosylation. Such agents would then be disposed within the filter medium in such fashion as to be in surface contact and fluid registry with smoke as it transits through the filter, to thereby capture and/or prevent the formation of advanced glycosylation endproducts.
- the present invention extends to a filter comprising a porous medium, prepared from fibers or other like suitable materials, which has included on its active surfaces, a quantity of an agent known to inhibit advanced glycosylation or capable of trapping by reaction therewith AGEs present in the tobacco smoke stream.
- Such derivatized filters and filter media will find application not only in diminishing or eliminating the AGEs in the primary smoke stream generated by the direct consumption of tobacco products by smoking, but also in diminishing or eliminating the ambient AGEs attendant to environmental exposure to tobacco smoke, such as in "secondary smoking," as the inhalation by bystanders of the tobacco smoke produced in the smoking activity of others nearby has come to be called.
- the techniques for the preparation of such filter media are otherwise known, and do not per se form a part of the present invention. Naturally, to the extent that specific procedures will attend the application of the agents of the present invention into active position on such filter media, such techniques are, in fact, a part hereof.
- a particular and important aspect of the present invention is the discovery that tobacco and its combustion byproducts contain reactive sugars much like those observed in other foods as well as in body fluids and tissues, which exhibit toxic effects on body systems of smokers and second-hand recipients of tobacco smoke.
- the present inventors examined and have consequently determined that tobacco and tobacco smoke contain and disseminate these reactive species which are known to increase AGE formation in vivo.
- glycotoxins are defined as reactive substances that may participate in, or may be formed during the Maillard reaction, which are comprised of either carbohydrate alone, or an adduct of carbohydrate and an amino-containing material, eg. protein, DNA, lipid, and all such like materials.
- glycotoxins react with protein, exhibit a specific fluorescence, crosslink proteins and are mutagenic.
- tobacco smoke contains significant quantities of glycotoxins, which glycotoxins can enter the circulation and react with serum and tissue proteins to form AGEs.
- Increased glycotoxin exposure may contribute to the increased atherosclerosis and high prevalence of cancer in smokers, and as set forth herein, an effective therapy is believed to reside with the use and administration of inhibitors of advanced glycation, such as aminoguanidine.
- the invention thus predicated on the relationship between the formation of advanced glycosylation endproducts and the preparation and consumption of tobacco.
- glycation reactants such as reactive sugars therein, in tobacco and tobacco smoke, and their transfer to smokers and bystanders lays the groundwork for a variety of applications, including without limitation, diagnostic and evaluative applications, therapeutic uses in connection with the inhibition of the of the accumulation of advanced glycosylation endproducts and the adverse sequelae thereof, and the treatment of tobacco materials both to potentiate their organoleptic properties and storage status, and more importantly, to reduce the deleterious effects of their use.
- the implementation of the principles of the present invention is facilitated by the body of research and knowledge that has resulted from the intimate investigation of the phenomenon of advanced glycosylation by the present inventors and the specific findings and observations disclosed herein.
- Figure 1 is a graph showing the AGE content of aqueous extracts of cigarette tobacco.
- AGE levels in phosphate buffer extracts of cigarette tobacco samples were quantified in a standardized competitive AGE immunoassay and calculated as Total AGE Units per Cigarette.
- Cigarette brands were: Gau, Gauloises; Mar, Marlboro; ML, Marlboro Light; Par, Parliament; Sal, Salem Ultra Lights.
- Figure 3 is a graph showing that glycotoxins, and reactive sugars and AGEs present in aqueous solutions of condensates of tobacco smoke are reactive with proteins in vitro.
- Collagen-coated assay plates were exposed to phosphate buffer-solubilized condensates of cigarette smoke, and AGEs formed on the collagen-treated assay plate wells were measured by an immunometric method whereby an increase in the final absorbance (optical density or OD) reflects increased AGE crosslinking to, and accumulation on, the collagen matrix of the assay plate.
- Figure 4 is a graph showing that Pimagedine (aminoguanidine) inhibits the in vitro reaction of cigarette smoke condensate extract with protein.
- Collagen-coated assay plates were exposed to aqueous extracts of condensates of cigarette smoke in the presence or absence of various concentrations of Pimagedine. AGEs formed on the collagen-treated assay plate wells were then measured by an immunometric method whereby an increase in the final absorbance (optical density or OD) reflects increased AGE crosslinking to, and accumulation on, the collagen matrix of the assay plate.
- optical density or OD optical density
- Figure 5 is a graph showing the glycotoxins (reactive AGEs or glycation intermediates) are found in aqueous extracts of tobacco and tobacco smoke.
- Glycotoxins were measured in aqueous extracts of tobacco in a competitive AGE assay (A) and in a direct binding immunoassay (B). Tobacco samples from four different brands of American cigarettes were extracted in PBS for 24 hrs, filter sterilized and assayed for AGE content in the competative AGE ELISA previously described. Each bar represents a different brand of cigarette (A). Total AGE Units per cigarette were calculated as an index of the AGE content of the extracts. Tobacco samples were extracted in PBS for 1 hour, filter sterilized and assayed for reactive sugar (glycotoxin) content utilizing rat tail tendon collagen immobilized in 96-well microtiter plates (B).
- A competitive AGE assay
- B direct binding immunoassay
- Figure 6 is a further series of graphs showing that glycotoxins are found in tobacco smoke.
- Glycotoxins can be removed by passing smoke through aminoguanidine. Fresh cigarette smoke was passed through a standard filter (black bar), a standard filter + 500 mg sodium sulfate (striped bar) and a standard filter + 500 mg aminoguanidine (white bar)
- C Glycotoxins from mainstream smoke can covalently crosslink RNAse A proteins (and this cross-linking is inhibited by aminoguanidine). RNAse A was exposed to mainstream cigarette smoke for 0, 5, 8, 24, 48 and 72 hours. To assess the formation of dimers, the samples were subjected to SDS-PAGE under reducing conditions, followed by transfer to nitrocellulose and western blotting with a rabbit anti-RNAse A antibody conjugated to HRP.
- D Glycotoxins have autofluorescence. RNAse A was exposed to mainstream cigarette smoke for 0, 5, 8, 24, 48 and 72 hours and then assayed for glycotoxin- specific fluorescence by measuring emmision at 440 nm upon exictation at 370 nm.
- Figure 7 is a graph demonstrating that glycotoxins are mutagenic.
- Salmonella strain TA98 was incubated for 1 hour with serial dilutions of condensate of cigarette smoke (Black bars), versus cigarette smoke passed through aminoguanidine (white bars) and then plated. Forty-eight hours later the number of colonies on each plate were counted. Each bar represents the mean of three plates +/- standard deviation.
- Figure 8 is a series of graphs showing that smoking causes increased levels of apoB-AGE and serum AGE in vivo.
- Serum apoB-AGE (A) and total AGE levels (B) were measured in healthy non-diabetic smokers and healthy, non-diabetic, non- smokers who work at the Picower Institute.
- Figure 9 is a graph showing the results of tests of tobacco that was treated by spraying with a range of concentrations of aminoguanidine, for the pu ⁇ ose of determining the effect of such treatment on the formation of AGEs. The tests were performed in accordance with the in vitro AGE formation assay described with reference to Figure 6.
- the present invention derives from the relationship that has been identified between the consumption of tobacco and the development of increased levels of advanced glycosylation endproducts in such individuals.
- Initial observations resulted from investigation of levels of advanced glycosylation endproducts in a particular test population and particularly, the conjunction of increased levels of apoB-AGE and coronary heart disease in such population and the discovery of a correlation or a link with the fact that the individuals exhibiting such increased levels were regular consumers of tobacco products.
- the initial observation prompted the study of the tobacco products themselves, which yielded the discovery that such products, including the combustion byproduct, smoke, contained high concentrations of advanced glycosylation endproducts and the glycotoxins that promote their formation.
- the result of these initial discoveries has prompted further investigations and has resulted in the development of the various aspects of the present invention related to both measurement and treatment modalities with respect to tobacco, smoke, smokers, and AGEs.
- the invention extends in its initial aspect to the examination of subjects having a history of smoking to better determine their smoking history, by measuring the increases of advanced glycosylation endproducts relative to a norm derived from a non-smoking population having otherwise a similar or identical medical profile.
- Such methods may be practiced by the examination of a variety of body tissues and fluids of the test subject, such as blood, urine and feces.
- the measurement of the presence and level of AGEs and glycotoxins would be useful in helping to predict the susceptibility of the test subject to diseases predicated at least in part, on the known mutagenic properties of AGEs and glycotoxins.
- the tobacco products themselves may be examined and evaluated to determine their potential for the promotion of increased AGE and glycotoxin levels in tobacco users.
- both the tobacco product itself and its combustion byproducts may be examined for the presence of such advanced glycosylation endproducts and/or the glycotoxins that would form them.
- the same products may be examined and the level of advanced glycosylation endproducts indexed with a view to determining the storage stability and flavor potential of a given tobacco crop. Such measurements would be developed against certain benchmarks or standards taken from like samples or populations as the case may be.
- a variety of specific implementations of the protein-browning assay and an AGE-trapping filter that may be prepared in accordance with the present invention also provides and exemplifies the essential elements required for a smoke-exposure dosimeter convenient for the estimation of the exposure of individuals to environmental smoke, especially tobacco smoke, based on the detection of AGEs that become cross-linked to protein amino groups or other susceptible chemical glycation targets.
- the risk of exposure to environmental tobacco smoke can be estimated using a dosimeter of the present invention that exposes glycation target molecules to the atmosphere of an environment in need of monitoring for tobacco smoke burden, wherein said dosimeter provides for said reactive air-borne AGEs and glycotoxins deriving from tobacco smoke to attach spontaneously to the AGE target molecules which are displayed on a matrix, thus comprising the capture elements of the dosimeter.
- the AGEs that become attached to the amino group-displaying matrix of the dosimeter may be visualized, qualitatively, semi-quantitatively or quantitatively, by any of a number of AGE-identifying methods well-known in the art including, without limitation, the AGE ELISA method utilizing anti-AGE antibodies as described supra, in steps that comprise the display elements of the dosimeter.
- Suitable glycation target molecules for incorporation in the capture elements of the dosimeter include not only various proteins, such as BSA, RNase, collagen and poly-lysine that are well-known as AGE susceptible target molecules, but also any other biomolecules or organic compounds that present amino groups which are susceptible to reaction with AGEs.
- Such glycation target molecules are preferably immobilized on the surface of a substrate which advantageously presents them to the atmosphere to be monitored; such as a paper surface derivatized to display amino groups, a nitrocellulose membrane surface similarly derivatized, a polystyrene filter surface likewise derivatized to present amino groups as glycation targets, or any other relatively inert matrix that presents glycation target molecules and is disposed to interact with the atmosphere of the environment to be monitored.
- Contact between the atmosphere to be monitored for tobacco smoke and the matrix-immobilized glycation target molecules, and circulation of said atmosphere over said capture elements, may be effected passively, as by convection, or actively, by any means that forces the atmosphere to flow over the capture elements, such as a fan.
- the amino-group presenting glycation target molecule may be dispersed in a liquid, and air from the environment to be monitored may be drawn through said liquid, for instance by bubbling.
- the glycation target molecules having been exposed to the atmosphere of the environment in need of monitoring, whether disposed on a matrix or within a fluid phase, are then examined by any suitable AGE-detecting method, such as specific implementation of the general AGE ELISA assay methods disclosed infra for the detection of AGEs, such that the detection of AGEs or glycotoxins by their reaction with the glycation target molecules will indicate the degree of contamination of the environmental atmosphere with tobacco smoke. Use of such dosimeters will correspondingly indicate the exposure of individuals to secondhand smoke in the environment.
- Similar methods of measurement may be employed to monitor the presence and amount of glycotoxins in tobacco products, and to thereby assess and rate their proclivity for deleterious effect on tobacco consumers and bystanders alike. For example, one may employ for such pu ⁇ ose the in vitro AGE formation assay presented herein to measure glycotoxins in tobacco extracts.
- the dosimeters and corresponding methods of measurement recited above may be applied in a therapeutic context, to monitor and evaluate the course of treatment of a particular patient whose malady is characterized by elevated levels of AGEs in body fluids and tissues. Accordingly, a sample taken from the patient may be tested to establish the extent of reaction of AGEs present in the sample, for instance, by an AGE ELISA or like test, to apprise the treating physician of the patient's progress under treatment. The physician may then choose to modify the treatment regimen within discretion, based upon the results of the test.
- the measurement of both the sample taken from the patient and the ambient air in which the patient spends a preponderant amount of time may suggest that the ambient should be remediated to reduce the exposure of the patient to additional sources of AGEs or glycotoxins, whether from tobacco smoke or other exogenous sources, and consequently, will further aid the physician in caring for the patient.
- various diagnostic assays, kits and the like may be prepared which would be specifically useful in accordance with the present invention, by the preparation of antibodies that are directed to the advanced glycosylation endproducts and glycotoxins found in tobacco and tobacco byproducts. Such antibodies may thereby be generated and thereby utilized as standards in diagnostic tests, as well as in the characterization of tobacco-related AGE and glycotoxin chemical structure.
- Suitable inhibitors of advanced glycation have been identified earlier, and include, for example, aminoguanidine (Pimagedine), its analogs, agonists, congeners, cognates and mimics, and mixtures thereof where appropriate.
- Other suitable inhibitors may be selected from among those active aldehydes, or compounds bearing a correspondingly active aldehyde substituent, that are reactive with the glycosyl-amino moiety of the early Amadori and Heyns products of the Maillard reaction, as identified supra, and mixtures and combinations thereof where appropriate.
- Additional suitable inhibitors may be selected from those thiazolium derivatives and other compounds and compositions thereof identified supra, which are reactive with ⁇ -dicarbonyl segments within existing AGEs, especially those of such compounds which promote or initiate cleavage of said ⁇ -dicarbonyl segments within said existing AGEs in a self-regenerating, catalytic fashion. The exact mode of administration would be upon the determination of a skilled physician.
- An alternative strategy with respect to smokers would be the direct treatment of the smoking materials that are being consumed. Such materials could be treated by similar inhibitors, so that the tobacco products receiving such treatment would have a reduced number of AGEs (and particularly a reduced number of glycotoxins and reactive AGEs), or a reduced capacity to promote the formation of such AGEs in the consumers.
- the invention extends to the preparation of filter materials that could be embodied in tobacco products such as cigarettes, so that the filters themselves would be capable of inhibiting, trapping, or otherwise neutralizing tobacco-related AGEs or related chemical entities that promote increased formation and transmittal of advanced glycosylation endproducts (eg. glycotoxins).
- the filter materials in turn are those that are conventionally provided and are fabricated for use in cigarettes, and are frequently fibrous material bundled together and bound into a cylindrical form in the finally assembled cigarette.
- Such fibrous materials of which cellulose fibers are representative, could contain on their surfaces an appropriate inhibitor or reactive agent that would serve to trap AGEs or to otherwise bind to or neutralize other glycation products such as glycotoxins, so as to prevent them from forming AGEs upon consumption.
- filters active in inhibiting, trapping, or otherwise neutralizing tobacco- or smoke-related AGEs or related entities that promote increased formation and transmittal of advanced glycation endproducts can be fabricated for use in general or environmental air purification, for instance to diminish or eliminate the ambient atmospheric AGEs and/or glycotoxins that would otherwise be undesirably consumed by indirect, passive or "secondhand" smoking.
- filters or like materials may be prepared to enable the sampling of the environment, whether by contact with ambient air, or by direct application to such materials or substrates to samples, biological or otherwise, where concentrations of AGEs or the glycotoxins that may form them, are suspected; for the pu ⁇ ose of instituting measures to reduce such AGE levels.
- Such measures may comprise the appropriate treatment of the environment to remediate those areas where AGE levels are undesirably elevated, or to institute or adjust the treatment of individuals located in that environment to reduce the internal AGE level or burden in such individuals.
- Particular such therapies include the administration of agents such as those referred to herein, that function as inhibitors of AGE formation, or that function to promote or effect the removal of AGEs from the body.
- the protein- browning assay and the AGE-inhibiting, AGE-trapping or AGE-neutralizing filters of the present invention also provide and exemplify the essential elements required for smoke-exposure dosimeters convenient for the estimation of the exposure of individuals to environmental smoke, especially tobacco smoke, based on the detection of AGEs that become cross-linked to protein amino groups or other susceptible chemical glycation targets.
- Example 1 is provided as illustrative of the experiments that have been performed to identify this relationship and to facilitate the implementation of the above inventive embodiments.
- Example 1 is provided as illustrative of the experiments that have been performed to identify this relationship and to facilitate the implementation of the above inventive embodiments.
- a competitive ELISA for AGEs is conducted according to general immunoassay procedures that are common in the art. Briefly, a Master Stock of AGE-modified BSA (AGE-BSA) was prepared by incubating BSA (Calbiochem, Cat. #12657, Fraction V, purity >99% by SDS-PAGE) at 50 mg/ml in 0.5 M glucose prepared in phosphate- buffered saline (PBS), pH 7.4, containing 1.0 mM EDTA and overlaid with a nitrogen atmosphere in sealed tubes for eight weeks at 37°C.
- BSA Calbiochem, Cat. #12657, Fraction V, purity >99% by SDS-PAGE
- 96-well microtiter assay plates (NUNC Maxiso ⁇ ) are coated with the standard antigen by incubating 100 ⁇ l of a solution of AGE-BSA at a concentration of 30 ⁇ g/ml in Coating Buffer (0.1 M NaHCO 3 /0.02% azide, pH 9.6) in each well overnight at 4°C, covered. Assay wells are then rinsed six times with 200 ⁇ l Wash Buffer (Tris-buffered saline with 0.05% Tween 20) using an automated ELISA plate washer, inverted, and blotted to dry.
- Coating Buffer 0.1 M NaHCO 3 /0.02% azide, pH 9.6
- Blocking Buffer PBS/2% normal goat serum/0.2% BSA/0.02% azide, pH 7.4
- the plate is incubated, covered, for 1 hour at 37°C.
- the standard AGE-BSA-modified assay plate is ready for use in the competitive ELISA.
- the assay method of the present Example was initiated by addition of a 50 ⁇ l aliquot of sample or AGE-BSA Standard Competitor to each well of an AGE-BSA- coated assay plate, followed by the immediate addition 50 ⁇ l of an appropriately titrated preparation of an anti-AGE antibody.
- the plate was then incubated, covered, for two hours at room temperature, during which period AGEs within the test sample (or the AGE-BSA standard) competed for binding with the primary or anti-AGE antibody against the AGEs immobilized on the assay plate in the form of AGE-BSA.
- a dilution series of AGE-BSA Standard Competitor was prepared by diluting AGE-BSA Master Stock to provide a concentration series ranging from about 0.1 to 2 ⁇ g AGE-BSA per well, and the equivalent concentration of AGE-BSA Standard Competitor corresponding to the final OD of each sample well could be inte ⁇ olated from this standard competition curve.
- One AGE Unit is operationally defined as the concentration of Standard Competitor AGE-BSA (in BSA mg/ml) required for 50% inhibition in this competitive AGE ELISA format.
- a 100 ⁇ l aliquot of substrate chromogen in this case, para-nitrophenyl phosphate (PNPP)
- PNPP para-nitrophenyl phosphate
- PNPP para-nitrophenyl phosphate
- the AGE level in any sample may then be inte ⁇ olated as the equivalent concentration of Standard Competitor AGE-BSA (in BSA mg/ml) from the standard competition curve, and this value is then typically converted into AGE Units where 1 AGE Unit is the concentration of Standard Competitor AGE-BSA that produces 50% inhibition in this competitive AGE ELISA method.
- cigarette smoke was drawn through a 1 ml sample of normal human serum using a "hookah” or water-pipe smoking device constructed from a small glass sidearm flask which was designed and operated not only to bubble a stream of smoke through the contained serum sample, but also to allow smoke to accumulate above, and in contact with, the serum sample, which exposure was maintained during an incubation period following the active "smoking" phase of exposure. Filters were removed from the cigarettes to be used, and a cigarette was mounted in a Pasteur pipette that penetrated the stopper of the flask to terminate with its tip submerged in the serum sample.
- this device was repeatedly operated to draw the smoke from five (5) cigarettes through the serum sample by suction applied with a syringe attachable to the sidearm. Approximately the same volume of air was drawn through a separate serum sample using an identical device except that no cigarette supplied smoke to the airstream for this control reaction. AGE levels in these experimentally treated serum samples were then measured by the standardized competitive AGE ELISA described above (see Example 1). This experiment was conducted twice independently, with comparable results in each case as shown in Figure 2. Thus, while control serum samples averaged less than 25 AGE Units per ml, smoke-exposed serum samples showed about 150 AGE Units per ml.
- condensates of tobacco smoke were assessed for reactive AGE content as follows.
- a sidearm flask was equipped with a stopper to which was fitted a short piece of rubber tubing with an Pasteur pipette attached.
- a syringe fitted to the sidearm was operated repeatedly to draw smoke from a total of 3-5 cigarettes into the flask, which was immersed during this period of smoke condensate collection in an acetone/dry ice bath.
- glycotoxins in these extracts was then assessed in an AGE formation assay that uses anti-AGE antibodies to detect the covalent attachment of AGEs to an immobilized collagen layer.
- an AGE formation assay that uses anti-AGE antibodies to detect the covalent attachment of AGEs to an immobilized collagen layer.
- commercially available 96-well micro titer plates with rat tail tendon collagen immobilized on the surface of the wells (Collaborative Research) were exposed to dilutions of the smoke condensate extracts described above and incubated overnight, covered, at room temperature.
- AGEs that become immobilized on the surface by interaction with the tail tendon collagen are then assayed in accordance with the immunometric procedures outlined above for the competitive AGE assay: smoke extract-treated collagen-coated plates were sequentially rinsed, exposed to the 4G9 monoclonal anti-AGE antibody, rinsed, exposed to a commercially available goat anti-mouse IgG/alkaline phosphatase conjugate, rinsed, and supplied with an appropriate chromogenic substrate (e.g. PNPP) to generate a signal measured by optical density at 410 nm which quantitatively reflects the amount of AGE-like immunoreactivity that had accumulated on the plate by exposure to the tobacco smoke condensate extract relative to controls not treated with smoke condensate extract.
- an appropriate chromogenic substrate e.g. PNPP
- Pimagedine (aminoguanidine), an AGE inhibitor active, among other things, in inhibiting AGE crosslink formation, was included at various concentrations during the overnight incubation of tobacco smoke condensate extracts in the rat tail tendon collagen-treated plates. As shown in Figure 4, Pimagedine decreased the amount of AGEs detected immunometrically in a dose-dependent fashion with about a 50% inhibition at about 50 mM Pimagedine.
- Tobacco samples were extracted in PBS at a concentration of 360 mg/ml for 1 hour with agitation and filter sterilized through a 0.45 ⁇ m Millex-HA filter unit (Millipore, Bedford, MA).
- the pipette tip was modified: A 2 mm x 2 mm piece of commercial cigarette filter was used to plug the tip of the pipette tip and then 500 mg of either nothing, aminoguanidine hydrochloride or sodium sulfate was placed between the small piece of filter and the cigarette. The pre-attached commercially prepared filters were not removed from the cigarettes in any of the experiments. Five cigarettes were smoked into each 3 ml aliquot of PBS. Before use the aqueous cigarette smoke condensate was filtered through a 0.45 um Millex-HA filter unit (Millipore).
- Microtiter plates containing immobilized rat tail tendon collagen were incubated with TBS (PBS/ 0.05% Tween-20) for 1 hour, then incubated with serial dilutions of either the tobacco extract or smoke- exposed PBS solution for 18 hours at 37°C, washed five times with TBS, incubated with a rabbit polyclonal anti-AGE sera (pAb RU 9.9.93 diluted in TBS/0.1 % goat serum) for 1 hour, washed five times with TBS and incubated with anti-rabbit IgG conjugated to alkaline phosphatase (Sigma) and washed five times with TBS.
- TBS PBS/ 0.05% Tween-20
- bound AGEs are revealed by incubating with 250 mg/ml p-nitrophenyl phosphate in 100 mM diethanolamine pH 9.5 for 45 minutes and plates were read at 405 nm on an ELISA plate reader (Dynatech, MR 5000). Biolynx 2.0 was used for generation of a standard curve and data extrapolation.
- RNAse A dissolved in PBS/EDTA containing either 0, 5 or 50 mM aminoguanidine was exposed to the equivalent of 8 cigarettes and incubated at 37°C in the dark for 0, 5, 8, 24, 48 and 72 hours. Unbound and low molecular weight materials were removed using a Centricon 10 concentrator (Amicon, Beverly, MA). To assess the formation of RNAse dimer formation, samples were subjected to discontinuous SDS-PAGE under reducing conditions using a 5% stacking gel and a 12% resolving gel [Nature 227:680-685, 1970] and transferred to nitrocellulose paper.
- the blot was blocked with blocking solution (PBS/5% non-fat milk/1% BSA/0.2% Tween-20) for 1 hour at 20°C, incubated with rabbit anti-ribonuclease A antibody conjugated to horseradish peroxidase (Biodesign International, Kennebunkport, ME) diluted in blocking solution for 45 minutes, washed extensively with PBS/0.2% Tween-20 and developed according to the manufacturer's directions.
- the resulting fluorograph was processed using Adobe Photoshop and densitometric measurements of images (smoothed, sha ⁇ ened and contrast enhanced) determined using the NIH image program.
- mutagenicitv studies The mutagenicity assay was performed as described by Ames et al. [ ] Briefly, Salmonella strains TA98, TA100, TA1535 and TA1537 (gift from Dr. B.N. Ames) were cultured overnight at 37°C in Oxoid nutrient broth (Difco), incubated with serial dilutions of cigarette smoke condensate in 0.1 M sodium phosphate buffer, pH 7.4, in triplicate for 1 hour and then plated on minimal glucose plates at a concentration of 0.1 ml/plate. The plates were then incubated overnight at 37°C and the number of revertant mutants on each plate was counted.
- AGE-modified apoB The amount of AGE-modified apoB (AGE-apoB) was measured in human serum by sandwich ELISA employing a monoclonal anti-AGE capture antibody and an anti-apoB-HRP conjugate as described previously (JBC, 267:5133-5138, 1992).
- apoB-AGE U/ml of serum One Unit of apoB-AGE is defined as the activity of 1 ⁇ g of apoB (LDL).
- AGE Measurement AGEs in human sera were measured by a competitive ELISA employing an AGE- specific monoclonal antibody (IgGl subclass) raised to a glucose-derived AGE epitope as previously described in (PNAS USA 90:6434-6438 and infra). AGE- immunoreactivity was determined in triplicate wells for samples which were serially diluted to fall within the linear range of the assay. AGE Units were calculated relative to a synthetic AGE-BSA standard. The assay sensitivity was 5 U AGE /ml and the intra- and inter-assay coefficient of variation was 5% and 8% respectively. Results
- Aqueous extracts of tobacco and cigarette smoke contain glycotoxins which promote AGE formation in vitro.
- the water soluble reactive glycotoxins were extracted from cigarette tobacco samples by soaking in PBS.
- the aqueous extract was added to collagen-coated plates for 18 hours. The presence of newly formed AGEs on the collagen molecules was detected using a specific anti-AGE polyclonal antibody.
- Figure 5A shows a comparison of the AGE formation induced by eight brands of American cigarettes. Extracts from all brands tested promoted the formation of
- cigarette smoke condensate was able to rapidly induce the formation of AGEs that were recognized by the rabbit anti-AGE polyclonal antisera.
- the production of AGEs by the cigarette smoke was concentration ( Figure 5B) and time (data not shown) dependent and could be inhibited in a dose- dependent manner by adding a soluble AGE inhibitor, aminoguanidine, directly to the wells (data not shown) or by passing the smoke through a column of aminoguanidine crystals ( Figure 5C). Passing the smoke through a control column of sodium sulfate had no effect on the ability of the smoke-borne tobacco-derived glycotoxins to form AGEs on the target ( Figure 5C).
- the cigarette smoke condensate was approximately ten-fold less active at promoting AGE formation than the aqueous tobacco extracts, which suggests that either some of the glycotoxins are destroyed by the burning process or that the system for capturing the volatile glycotoxins and AGEs is inefficient.
- the AGE forming activity found in both the tobacco leaf extract and the cigarette smoke condensate was labile: it was undetectable if the solutions were frozen at -20°C and thawed before testing, or left sitting on ice or at room temperature for greater than 5 hours.
- RNAse A exposed to cigarette smoke condensate for increasing amounts of time exhibited a time-dependent increase in AGE-typical fluorescence, (i.e., emission at 410 after excitation at 370 nm), that reached saturation after 24 hours and was inhibited by the presence of aminoguanidine during the incubation.
- Glycotoxins can cross-link proteins
- One of the hallmarks of reactive reducing sugars is that they promote the formation of intra- and inter-molecular crosslinks between the susceptible functional groups.
- we assayed glycotoxins for their ability to crosslink RNAse A Samples of RNAse A were incubated with cigarette smoke condensate for various amounts of time, separated by molecular weight on an SDS-PAGE gel and then visualized with anti-RNAse A antisera. Using this technique, Applicants were able to determine that RNAse A-RNAse A dimer formation was time dependent and reached saturation within 24 hours. Dimer formation could be inhibited by aminoguanidine in a dose-dependent manner, indicating that the crosslinking process was dependent on carbonyl-containing glycotoxins (Figure 6B).
- Glycotoxins are mutagenic
- an anti-AGE antibody is immobilized on the surface of the assay wells to capture AGE-modified components of the sample, and a commercially available anti-apoB monoclonal antibody/horseradish peroxidase (HRP) conjugate is used to detect any AGE-modified apoB so immobilized by specific binding interaction with the immobilized anti-AGE antibodies.
- HRP horseradish peroxidase
- a low-density lipoprotein (LDL)-enriched serum fraction was prepared by treating a 100 ⁇ l serum sample with 900 ⁇ l 6.66% polyethylene glycol, m.w. 8000, for 15 minutes, centrifuging (14,000 rpm, 10 minutes), and solubilizing the resulting pellet in 100 ⁇ l 0.5% SDS overnight.
- an anti- AGE antibody in this case the monoclonal antibody 4G9, is immobilized onto the surface of a micro titer plate by incubation at a titrated dilution, after which non ⁇ specific binding is blocked by replacing the capture antibody solution with a 1% solution of BSA.
- LDL-enriched serum fractions are then incubated in triplicate in the assay plates in a final concentration of 0.05% ⁇ SDS in buffer and incubated for one hour, at which time the plates are rinsed and a titrated dilution of commercially available anti-apoB monoclonal antibody/enzyme conjugate (in this case anti-apoB/horseradish peroxidase (HRP) conjugate purchased from Biodesign International and used at 1 :500 dilution) is added to detect any bound apoB.
- HRP anti-apoB/horseradish peroxidase
- a suitable chromogenic HRP substrate such as o-phenyline diamine (OPD) is added and, after an appropriate incubation period, OD is read at 450 nm versus a 570 nm reference wavelength.
- OPD o-phenyline diamine
- optimal concentrations of various reagents e.g., the coating antibody and the detector antibody
- optimal pH, detergent concentrations, buffer compositions, incubation periods, and other particular features are varied one against the other in order to maximize the sample signal and minimize interfering non-specific background "noise" in this sandwich-type immunometric assay for AGE-modification of apoB.
- the pre-smoking AGE-apoB value in this experiment was 218 + 1 and the post- smoking value was 241 ⁇ 3 apoB-AGE Units per mg apoB (where one apoB-AGE Unit is defined as the activity of 1 ⁇ g/ml of a commercially available LDL standard (e.g., from Cappel).
- AGE modification of LDL has been linked to pathogenic mechanisms that adversely affect human health, this further suggested to Applicants that smokers might benefit from interventions to limit excess AGE exposure that occurs as a result of tobacco consumption.
- the AGEs of tobacco and tobacco products including, for example, tobacco smoke also find utility as antigens or haptens, to elicit antibodies specifically directed to tobacco-related AGE structures.
- Such antibodies likewise of the present invention, are useful in turn to identify and inhibit tobacco-related AGE structures.
- immunoassays employing anti -tobacco-related AGE antibodies of the present invention, for instance, the degree to which proteins are modified by tobacco-related AGEs can be measured.
- immunochemical measurement of AGE epitopes on a protein sample such as serum proteins, provides an index of recent tobacco consumption, e.g. by smoking.
- immunochemical detection of AGE epitopes on circulating and/or tissue proteins can be used to monitor the course of treatment with agents of the present invention, which agents are directed toward inhibition of the excess accumulation of AGEs through tobacco use by reacting with AGEs in tobacco or tobacco smoke.
- haptens, antigens, and conjugated immunogens corresponding to the tobacco-related AGEs of the present invention can conveniently be prepared, either by isolation of tobacco-related AGEs from tobacco or from tobacco smoke, for instance by making an AGE-containing aqueous extract of tobacco or of tobacco smoke condensate, as described above. This extract may then be used as an immunogen to raise a variety of antibodies which recognize specific epitopes or molecular features thereof.
- the AGEs of the extract are considered haptens, which are correspondingly coupled to any of several preferred carrier proteins, including for instance keyhole limpet hemocyanin (KLH), thyroglobulin, and most preferred, bovine serum albumin (BSA), using any of a number of well-known divalent coupling reagents such as a carbodiimide like EDC, according to protocols widely circulated in the art.
- KLH keyhole limpet hemocyanin
- BSA bovine serum albumin
- the tobacco-related AGEs may be employed in any well-recognized immunization protocol to generate antibodies and related immunological reagents that are useful in a number of applications owing to the specificity of the antibodies for molecular features of the tobacco-related product.
- any of several animal species may be immunized to produce polyclonal antisera directed against the tobacco-related AGE protein conjugate, including for instance mice, rats, hamsters, goats, rabbits, and chickens.
- the first of three of the aforesaid animal species are particularly desired choices for the subsequent production of hybridomas secreting hapten-specific monoclonal antibodies.
- the production of said hybridomas from spleen cells of immunized animals may conveniently be accomplished by any of several protocols popularly practiced in the art, and which describe conditions suitable for immortalization of immunized spleen cells by fusion with an appropriate cell line, e.g. a myeloma cell line.
- Said protocols for producing hybridomas also provide methods for selecting and cloning immune splenocyte/myeloma cell hybridomas and for identifying hybridomas clones that stably secrete antibodies directed against the desired epitope(s).
- Animal species such as rabbit and goat are more commonly employed for the generation of polyclonal antisera, but regardless of whether polyclonal antisera or monoclonal antibodies are desired ultimately, the hapten-modified carrier protein typically is initially administered in conjunction with an adjuvant such as Complete Freund's Adjuvant.
- Immunizations may be administered by any of several routes, typically intraperitoneal, intramuscular or intradermal; certain routes are preferred in the art according to the species to be immunized and the type of antibody ultimately to be produced.
- booster immunizations are generally administered in conjunction with an adjuvant such as alum or Incomplete Freund's Adjuvant.
- Booster immunizations are administered at intervals after the initial immunization; generally one month is a suitable interval, with blood samples taken between one and two weeks after each booster immunization.
- hyperimmunization schedules which generally feature booster immunizations spaced closer together in time, are sometimes employed in an effort to produce anti-hapten antibodies preferentially over anti-carrier protein antibodies.
- the antibody titers in post-boost blood samples can be compared for hapten- specific immune titer in any of several convenient formats including, for instance, Ouchterlony diffusion gels and direct ELISA protocols.
- a defined antigen is immobilized onto the assay well surface, typically in a 96-well or microtiter plate format, followed by a series of incubations separated by rinses of the assay well surface to remove unbound binding partners.
- the wells of an assay plate may receive a dilute, buffered aqueous solution of the hapten/carrier conjugate, preferably wherein the carrier protein differs from that used to immunize the antibody-producing animal to be tested; e.g. serum from tobacco-related AGE/KLH conjugate-immunized animal might be tested against assays wells decorated with immobilized tobacco-related AGE/BSA conjugate.
- the assay surface may be decorated by incubation with the hapten alone.
- the surface of the assay wells is then exposed to a solution of an irrelevant protein, such as casein, to block unoccupied sites on the plastic surfaces.
- the well After rinsing with a neutral buffered solution that typically contains salts and a detergent to minimize non-specific interactions, the well is then contacted with one of a serial dilution series of anti-serum prepared from the blood sample of interest (the primary antiserum). After rinsing again, the extent of test antibodies immobilized onto the assay wells by interaction with the desired hapten or hapten/carrier conjugate can be estimated by incubation with a commercially available enzyme-antibody conjugate, wherein the antibody portion of this secondary conjugate is directed against the species used to produce the primary antiserum; e.g.
- the secondary antibody if the primary antiserum was raised in rabbits, a commercial preparation of anti-rabbit antibodies raised in goat and conjugated to one of several enzymes, such as horseradish peroxidase, can be used as the secondary antibody. Following procedures specified by the manufacturer, the amount of this secondary antibody can then be estimated quantitatively by the activity of the associated conjugate enzyme in a colorimetric assay. Many related ELISA or radioimmunometric protocols, such as competitive ELISAs or sandwich ELISAs, all of which are well known in the art, may optionally be substituted, to identify the desired antisera of high titer; that is, the particular antisera which give a true positive result at high dilution (e.g. greater than 1/1000 and more preferably greater than 1/10,000).
- Similar immunometric protocols can be used to estimate the titer of antibodies in culture supernatants from hybridomas prepared from spleen cells of immunized animals.
- control incubations e.g. with different carrier proteins, related but structurally distinct haptens or antigens, and omitting various reagents in the immunometric procedure in order to minimize non-specific signals in the assay and to identify reliable determinations of antibody specificity and titer from false positive and false negative results.
- the types of control incubations to use in this regard are well known.
- the same general immunometric protocols subsequently may be employed with the antisera identified by the above procedures (i.e., antibodies found to be of high titer and to be directed against specific structural determinants of tobacco-related AGEs).
- antisera identified by the above procedures i.e., antibodies found to be of high titer and to be directed against specific structural determinants of tobacco-related AGEs.
- Such latter applications of the desired anti-tobacco-related AGE antibodies, whether polyclonal or monoclonal, together with instructions and optionally with other useful reagents and diluents, including, without limitation, a set of molecular standards of the tobacco-related AGES, may be provided in kit form for the convenience of the operator.
- Anti-tobacco-related-AGE antibodies generated as described, and particularly such monoclonal antibodies also find use in the identification, separation, enrichment and purification of tobacco-related AGE epitopes. This may be accomplished by techniques known in the art, for instance, by exposing preparations known to contain the epitope of interest to immobilized antibodies specific for said epitope, washing away unbound material, and then eluting the specifically bound material and analyzing its chemical structure to determine specific molecular forms of tobacco-related AGEs.
- Attachment of reactive AGEs from tobacco or smoke extracts causes the protein surface to become colored with yellow and brown AGE pigments, in a manner analogous to the staining of skin, a mucosal surface or the tooth pellicle of tobacco users.
- Prevention of the accumulation of AGEs as evidenced by the prevention of accumulation of yellow/brown pigments with reference to control disks not incubated with the test agent, identifies AGE- inhibiting agents useful in the context of the present invention.
- protein-covered disks are "pre- browned" by incubation with the diluted tobacco extract or tobacco smoke condensate extracts as described supra, and a candidate AGE-reversing agent of the present invention is added to the incubation solution for a further period of time.
- Inhibition or reversal of the accumulation of yellow/brown pigments by test agents of the present invention by reference to control disks not incubated with the test agent, identifies candidates particularly suitable for use as AGE-reversing agents in the context of the present invention.
- AGE-inhibiting and AGE-reversing agents so identified are particularly suitable for formulation as an oral rinses or as a dentifrice to prevent or reverse undesirable tooth staining and pigmentation of other oral surfaces that occurs in conjunction with tobacco use, whether orally as with chewing tobacco and snuff, or by smoking as with cigarettes, cigars and pipe tobacco.
- Test agents with activity in this protein-browning assay may also be formulated into creams, emollients or the like for use on the stained hands and fingers of tobacco smokers. This method also exemplifies a method of dosimetry useful in monitoring environmental smoke exposure.
- mainstream smoke is generated from type IR3 non-filter research cigarettes (Tobacco Health Research Institute; Lexington, KY) using continuous smoking machines. Control animals are identically housed but exposed to the filtered airstream only, without cigarette smoke. Smoke exposure levels are determined by reference to gravimetric analysis of filter samples taken from the exposure chambers. The chemical and physical characteristics of this smoke-exposure atmosphere have been described in detail (vide supra and J. Chen et al, 1992, J. Aerosol Med. 5:19-30).
- test animals are sacrificed and various organs and tissues including, for instance, whole blood, are recovered and sampled for anatomical, microscopic, and biochemical analysis such as quantitation of AGE levels.
- serum is diluted 1 :5 in phosphate-buffered saline (PBS) and Proteinase K is added to 1/100 the mass of total serum protein in the sample.
- Serum proteins then are digested by incubation at 37°C, and Proteinase K is inactivated by raising the temperature to 70 °C for 1 hour. After a brief centrifugation to clarify, the supernatants are collected and brought to 1 mM phenymethyl sulfonyl fluoride (PMSF) before analysis for AGE content by AGE ELISA as described supra.
- PMSF phenymethyl sulfonyl fluoride
- the above method also provides a convenient assay by which to estimate the activity of agents and filter devices of the present invention in inhibiting, preventing or reversing the accumulation of AGEs due to tobacco consumption, as either the tobacco itself, the primary or mainstream tobacco smoke, the smoke-laden atmosphere, or the smoke- exposed animals may be treated according to the present invention, and the tissues and blood of the test animals then examined to determine the degree to which AGE accumulation thereby has been diminished, prevented or reversed by comparison to untreated or unexposed control samples.
- the examiner assembled pairs containing one of each type of cigarette (i.e. aminoguanidine or salt) and marked one of the pair with a small yellow dot.
- the cigarettes were then placed in a #10 envelope along with a smaller sealed envelope that contained the code (i.e. which cigarette had the yellow dot).
- the cigarettes with the aminoguanidine filter-add-in were marked with a yellow dot and in the other half the cigarettes with the sodium chloride filter-add-in were marked with a yellow dot.
- glycotoxin (AGE) removal filter is able to prevent cigarette smoke from staining of protein-coated surfaces.
- AGE glycotoxin
- Test cigarettes containing aminoguanidine or sodium chloride filter-add-ins were prepared described in Example 4 and smoked in the apparatus also described therein.
- Five mis of PBS were placed in a 25 ml glass erhlemeyer flask with a sidearm and 20 cigarettes with either of the two different types of filter add-ins were successively mounted in a 500 ul pipette tip that penetrated the hole in the stopper of the flask and burned. Approximately 20 mm Hg was applied to the sidearm of the flask to draw smoke into the flask and into contact with the PBS. After all 20 cigarettes were burned, 5 additional mis of fresh PBS were added and then 2 mis of the mixture was added to each of three wells in a 6-well plate.
- Each 6-well plate had three wells with PBS exposed to smoke from the cigarettes with the aminoguanidine filter-add-ins and three wells with PBS exposed to smoke from the cigarettes with the sodium chloride filter-add-ins. Plates were incubated for 48 hours at 37°C in the dark. Wells were then washed 6 times with PBS containing 0.05% Tween-20 and the color in the bottoms of the wells was compared. The color remaining in the wells was the colored AGEs that formed as a result of the interaction of the glycotoxins and/or reactive AGEs and the collagen-coated wells. Wells incubated with PBS exposed to smoke from the cigarettes with the sodium chloride filter-add-ins appeared brown in color while the wells incubated with PBS exposed to smoke from the cigarettes with the aminoguanidine filter-add-ins were not colored.
- Both aqueous extracts of tobacco and cigarette smoke contain glycotoxins, highly reactive reducing sugars or glycation intermediates that can rapidly induce AGE formation on proteins in vitro and in vivo and cause DNA mutations in vitro. Both of these activities can be removed from the samples by passing the smoke through a dry column of aminoguanidine, a potent and specific inhibitor of the formation of AGEs.
- Glycotoxins from cigarette smoke have a number of unique characteristics which distinguish them from the previously studied reducing sugars, glucose and glucose- 6-phosphate. Foremost is their extreme reactivity: In marked contrast to glucose or glucose-6-phosphate both of which have been reported to take days to weeks to induce measurable AGE formation, tobacco-derived glycotoxins can induce AGE formation in hours. While most reducing sugars, such as glucose, require transport to gain access to the cell cytoplasm, glycotoxins appear to readily cross cell membranes of bacterial cells. In addition, glycotoxins can be absorbed through the lungs from cigarette smoke and in turn react with serum proteins in healthy people.
- glycotoxins Although we have not determined the chemical structure(s) of glycotoxins, we can surmise that they have carbonyl groups and probably dicarbonyls since they are removed or quenched by aminoguanidine. Glycotoxins are probably a product of the rearrangement of products formed during the Maillard reaction which is initiated during the tobacco curing process. The instability of the glycotoxins during isolation implies that they and other Maillard products, which likely are responsible for the aroma and flavor of smoke, are constantly being formed and lost as the tobacco is cured and then as it ages.
- AGEs in vivo by tobacco glycotoxins, may be in part responsible for the increased incidence of atherosclerosis in cigarette smokers.
- AGEs have been shown to crosslink connective tissue collagen which serves to increase connective tissue rigidity.
- Collagen-linked AGEs serve as reactive "foci" to covalently trap circulating serum proteins, such as lipoproteins.
- Binding of an endothelial cell's AGE receptors will increase vascular permeability, decrease synthesis of the anti-coagulant thrombomodulin and increase synthesis of the procoagulant tissue factor.
- Exogenous AGE-modified albumin injected intravascularly into normal young rats and rabbits causes vascular alterations similar to those seen in animals with age- and diabetes-related vascular disease.
- Animals injected with exogenous AGE albumin show increases in vascular wall permeability, increased mononuclear cell migratory activity in subendothelial and periarteriolar spaces and defective blood pressure response after challenge with acetylcholine and nitroglycerin. [Vlassara et al PNAS 89: 12043-12047, 1992]. It is reasonable to expect that the AGEs formed by the reaction of glycotoxins with serum and tissue proteins would have the same activities as the previously described AGEs.
- Glycotoxins may also contribute to the increased incidence of cancer in cigarette smokers.
- reducing sugars can also react with the amino groups of nucleic acids.
- In vitro the incubation of either DNA or single nucleotides with reducing sugars produced absorbance and fluorescence changes similar to those observed for the AGE compounds bound to proteins and lipids.
- the incubation of bacterial plasmid DNA or mammalian shuttle vector DNA incubated with glucose or glucose-6-phosphate displayed considerable increase in mutation rates. (Bucala et al, 1984, PNAS 1984, 81:105-109; Bucala 1985, PNAS 82:8439-8442; Lee AT and Cerami, A.
- Mammals with diabetes do not have a demonstrable increase in any type of cancer even though they have elevated serum glucose levels.
- Glucose does not freely enter mammalian cells; it requires the presence of insulin to stimulate its transport. Therefore in adult mammals, the intracellular glucose concentration is independent of the serum glucose level.
- glycotoxins are far more potent than glucose. Like glucose and glucose-6-phosphate they can cause insertion and/or deletion mutants in an aminoguanidine-dependent manner, but unlike these other reducing sugars, glycotoxins can readily cross cell membranes.
- glycotoxins found in cigarette smoke, are responsible in part for the increased rates of atherosclerotic vascular disease and cancer seen among cigarette smokers.
- high concentrations of glycotoxins are inhaled into the alveoli where they may be both absorbed into the blood stream and taken up into the lung parenchymal cells.
- glycotoxins Once in the blood stream glycotoxins may induce the formation of AGE moieties on both serum and vascular wall proteins and thereby accelerate the development of atherosclerosis.
- Glycotoxins may also react with nucleic acids in the nuclei of the lung parenchymal cells to induce mutations and possibly cancer.
Abstract
Procédés qui permettent de mesurer l'accumulation de produits terminaux de glycosylation poussée (AGE) et de réduire cette accumulation desdits produits, fondés sur la découverte selon laquelle ces AGE et leurs glycotoxines précédentes sont présents dans le tabac et dans ses sous-produits. Plus particulièrement, lesdits procédés sont fondés sur l'observation selon laquelle les sujets qui fument ou utilisent du tabac d'une autre manière présentent des taux élevés d'AGE par rapport à des sujets non fumeurs. Les procédés de la présente invention concernent la mesure des taux d'AGE chez ces deux types de sujets et dans le tabac et son sous-produit qu'est la fumée, et le traitement de ces sujets avec des agents capables d'entrer en réaction avec les produits de glycosylation afin soit d'éviter soit de réduire l'accumulation d'AGE dans le corps. Des procédés concernent également l'évaluation des tabacs pour déterminer leur état de stockage et leur capacité et potentiel organoleptiques, le traitement de l'atmosphère ambiante pour réduire le taux d'AGE, et le traitement des tabacs et des sous-produits de combustion afin d'en réduire les taux d'AGE. Par exemple, de l'air et d'autres échantillons peuvent être prélevés et évalués à l'aide d'un dosimètre ou dispositif analogue, pour déterminer si les taux d'AGE sont supérieurs à la normale, après quoi des mesures pourraient être prises pour améliorer l'air ambiant. Des filtres et dispositifs similaires destinés à éliminer les AGE de la fumée du tabac sont également décrits. Tous ces procédés et les matériaux correspondants sont décrits et inclus dans la présente invention.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ326162A NZ326162A (en) | 1995-12-26 | 1996-12-23 | Methods for measurement and treatment predcated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts |
EP96944987A EP0877943A1 (fr) | 1995-12-26 | 1996-12-23 | Procede de mesure et de traitement fondes sur la presence de produits terminaux de glycosylation poussee dans le tabac et dans ses sous-produits de combustion |
AU13459/97A AU723649B2 (en) | 1995-12-26 | 1996-12-23 | Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts |
BR9612292A BR9612292A (pt) | 1995-12-26 | 1996-12-23 | Métodos para meditação e tratamento baseado na presença de produtos finais de glicosilação avançada no tabaco e seus subprodutos de combustão |
JP9523846A JP2000507346A (ja) | 1995-12-26 | 1996-12-23 | タバコ及びその燃焼副産物中の高次糖付加最終生成物の存在を基にする測定方法及び治療方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US921895P | 1995-12-26 | 1995-12-26 | |
US921995P | 1995-12-26 | 1995-12-26 | |
US60/009,219 | 1995-12-26 | ||
US60/009,218 | 1995-12-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997023783A1 WO1997023783A1 (fr) | 1997-07-03 |
WO1997023783A9 true WO1997023783A9 (fr) | 1997-10-23 |
Family
ID=26679210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/020526 WO1997023783A1 (fr) | 1995-12-26 | 1996-12-23 | Procede de mesure et de traitement fondes sur la presence de produits terminaux de glycosylation poussee dans le tabac et dans ses sous-produits de combustion |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0877943A1 (fr) |
JP (1) | JP2000507346A (fr) |
CN (1) | CN1211321A (fr) |
AU (1) | AU723649B2 (fr) |
CA (1) | CA2241924A1 (fr) |
IN (1) | IN191280B (fr) |
WO (1) | WO1997023783A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5921248A (en) * | 1997-03-28 | 1999-07-13 | The Picower Institute For Medical Research | Tobacco combination product filter |
EP1175155A4 (fr) * | 1999-04-15 | 2005-10-19 | Fox Chase Cancer Ct | Procede destine a reduire la predisposition a la formation de tumeurs provoquees par la 3-desoxyglucosone et les precurseurs de cette substance |
TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
SE0400683D0 (sv) | 2004-03-19 | 2004-03-19 | Forskarpatent I Syd Ab | Use of modified extracellular matrix proteins in diagnosis and treatment of a atherosclerosis |
CN106353434B (zh) * | 2016-10-21 | 2018-10-09 | 中国烟草总公司郑州烟草研究院 | 一种定量测定烟草中Amadori化合物的分析方法 |
CN106769349B (zh) * | 2017-01-06 | 2020-01-21 | 上海君联医疗设备有限公司 | 血液中异常糖基化蛋白细胞的检测方法 |
CN107202843B (zh) * | 2017-06-07 | 2019-08-30 | 贵州省烟草科学研究院 | LC-MS/MS法同时测定烟草中游离氨基酸和Amadori化合物的方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4665192A (en) * | 1984-03-19 | 1987-05-12 | The Rockefeller University | 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole |
US5869534A (en) * | 1992-05-21 | 1999-02-09 | The Picower Institute For Medical Research | Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom |
US4827949A (en) * | 1987-09-16 | 1989-05-09 | Sunas Ernest C | Method of treating tobacco and tobacco produced thereby |
CA1332572C (fr) * | 1988-01-29 | 1994-10-18 | Anthony Cerami | Methode et agents de prevention de la formation de taches sur les dents |
US5624804A (en) * | 1991-12-20 | 1997-04-29 | The Rockefeller University | Immunochemical detection of In vivo advanced glycosylation end products |
CA2210684C (fr) * | 1995-01-18 | 2008-01-15 | Alteon Inc. | Utilisation de composes de thiazolium pour empecher et inverser la formation de produits finis de glycosylation avancee |
-
1996
- 1996-12-23 CN CN96180126A patent/CN1211321A/zh active Pending
- 1996-12-23 JP JP9523846A patent/JP2000507346A/ja active Pending
- 1996-12-23 CA CA002241924A patent/CA2241924A1/fr not_active Abandoned
- 1996-12-23 EP EP96944987A patent/EP0877943A1/fr not_active Withdrawn
- 1996-12-23 WO PCT/US1996/020526 patent/WO1997023783A1/fr not_active Application Discontinuation
- 1996-12-23 AU AU13459/97A patent/AU723649B2/en not_active Ceased
- 1996-12-26 IN IN2949DE1996 patent/IN191280B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Schleicher et al. | Increased accumulation of the glycoxidation product N (epsilon)-(carboxymethyl) lysine in human tissues in diabetes and aging. | |
Rijcken et al. | Airway hyperresponsiveness to histamine associated with accelerated decline in FEV1. | |
Foiles et al. | Mass spectrometric analysis of tobacco-specific nitrosamine-DNA adducts in smokers and nonsmokers | |
Crawford et al. | Biomarkers of environmental tobacco smoke in preschool children and their mothers | |
Morrow et al. | The isoprostanes: current knowledge and directions for future research | |
Scherer et al. | Relationship between machine-derived smoke yields and biomarkers in cigarette smokers in Germany | |
US6110968A (en) | Methods for treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts | |
US5850840A (en) | Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts | |
Djordjevic et al. | Self-regulation of smoking intensity. Smoke yields of the low-nicotine, low-‘tar’cigarettes | |
Llaquet et al. | Biological matrices for the evaluation of exposure to environmental tobacco smoke during prenatal life and childhood | |
AU723649B2 (en) | Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts | |
WO1997023783A9 (fr) | Procede de mesure et de traitement fondes sur la presence de produits terminaux de glycosylation poussee dans le tabac et dans ses sous-produits de combustion | |
Rosenthal et al. | Time-course of cigarette smoke contamination of clinical hydrogen breath-analysis tests. | |
Clark et al. | Passive smoking amongst asthmatic children. Questionnaire or objective assessment? | |
Kraal et al. | The response of polymorphonuclear leukocytes to chemotictic stimulation for smokers and non‐smokers | |
US5688653A (en) | 3-alkylamino-2-hydroxy-4-hydroxymethyl-2-cyclopenten-1-one advanced glycosylation endproducts and methods of use therefor | |
US20050005946A1 (en) | Process and apparatus for the removal of toxic components of tobacco smoke and the standardization of the health hazards related to those components | |
US5854000A (en) | Methods for measurement predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts | |
AU4252700A (en) | Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts | |
Behera et al. | Serum surfactant protein-A levels in chronic bronchitis and its relation to smoking | |
MXPA98005261A (en) | Methods to measure and treat the pre-calculated calculation on the presence of final products of advanced glicosilation in tobacco and in its combust subproducts | |
Halmai et al. | Cigarette smoke elicits relaxation of renal arteries | |
Elmahdi et al. | Cytological changes and immunocytochemistry expression of p53 in oral mucosa among waterpipe users in the Kingdom of Saudi Arabia | |
Tso et al. | Simple correlation and multiple regression among leaf characteristics, smoke components, and biological responses of bright tobaccos | |
Larson | Metabolism of nicotine and nature of tobacco smoke irritants |